시장보고서
상품코드
1472053

섬유아세포 성장인자 시장 : 세계 산업 분석, 규모, 점유율, 성장, 동향 및 예측(2024-2031) - 제품, 용도, 최종 사용자, 지역 및 기업별

Fibroblast Growth Factors Market - Global Fibroblast Growth Factors Industry Analysis, Size, Share, Growth, Trends, and Forecast 2024-2031 - (By Product Coverage, By Application Coverage, By End User Coverage, By Geographic Coverage and By Company)

발행일: | 리서치사: Fairfield Market Research | 페이지 정보: 영문 185 Pages | 배송안내 : 2-5일 (영업일 기준)

    
    
    


※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계 섬유아세포 성장인자(FGF) 시장 규모는 2024년 약 2억 8,000만 달러에서 2031년 5억 달러로 크게 확대될 것으로 예상되며, 급격한 성장세를 보일 것으로 예상됩니다. 이 시장은 2024년부터 2031년까지 8.64%라는 놀라운 CAGR로 확대될 것으로 예상됩니다.

2024년부터 2031년까지 시장 매출은 1.7배 이상 성장할 것으로 예상되며, 이는 다양한 치료 분야에서 수요와 채택이 증가함에 따른 것으로 분석됩니다.

FGF는 상처 치유, 조직 재생, 종양학, 피부과, 심혈관 질환, 신경 질환 등 다양한 분야에 적용되고 있으며, 여러 분야에서 급성장하고 있는 치료 가능성을 보여주고 있습니다.

FGF 시장의 확대는 의료비 지출 증가, 생명공학 기술 발전, 치료 분야에서의 응용 분야 확대 등 여러 요인에 의해 촉진되어 강력한 성장 궤도를 보이고 있습니다.

이 보고서는 세계 섬유아세포 성장인자 시장에 대해 조사했으며, 시장 개요와 함께 제품별/용도별/최종사용자별/지역별 동향, 시장 진출기업의 경쟁 동향 등을 조사하여 전해드립니다.

목차

제1장 주요 요약

제2장 시장 개요

  • 시장 정의와 세분화
  • 시장 역학
  • 밸류체인 분석
  • Porter의 Five Forces 분석
  • COVID-19의 영향 분석
  • 우크라이나·러시아 분쟁의 영향
  • 경제 개요
  • PESTLE 분석

제3장 세계의 섬유아세포 증식인자 시장 전망, 2019년-2031년

  • 세계의 섬유아세포 증식인자 시장 전망, 제품별, 금액(10억 달러), 2019년-2031년
  • 세계의 섬유아세포 증식인자 시장 전망, 용도별, 금액(10억 달러), 2019년-2031년
  • 세계의 섬유아세포 증식인자 시장 전망, 최종사용자별, 금액(10억 달러), 2019년-2031년
  • 세계의 섬유아세포 증식인자 시장 전망, 지역별, 금액(10억 달러), 2019년-2031년

제4장 북미의 섬유아세포 증식인자 시장 전망, 2019년-2031년

제5장 유럽의 섬유아세포 증식인자 시장 전망, 2019년-2031년

제6장 아시아태평양의 섬유아세포 증식인자 시장 전망, 2019년-2031년

제7장 라틴아메리카의 섬유아세포 증식인자 시장 전망, 2019년-2031년

제8장 중동 및 아프리카의 섬유아세포 증식인자 시장 전망, 2019년-2031년

제9장 경쟁 구도

  • 최종사용자별과 용도별 히트맵
  • 기업의 시장 점유율 분석, 2023년
  • 경쟁 대시보드
  • 기업 개요
    • Thermo Fisher Scientific
    • Sigma-Aldrich(now part of Merck KGaA)
    • PeproTech
    • R&D Systems(a Bio-Techne brand)
    • Abcam
    • Cell Signaling Technology
    • Novus Biologicals

제10장 부록

LSH 24.05.08

Global fibroblast growth factors (FGF) market is poised to experience a substantial surge, with projections indicating a remarkable expansion to US$500 million by 2031 from approximately US$280 million in 2024. This forecast reflects an impressive compound annual growth rate (CAGR) of 8.64% during the period spanning 2024 to 2031.

Significant Revenue Surge:

The market anticipates more than a 1.7x expansion in revenue between 2024 and 2031, propelled by increasing demand and adoption across various therapeutic applications.

Diverse Applications:

FGFs find applications in diverse fields such as wound healing, tissue regeneration, oncology, dermatology, cardiovascular diseases, and neurological disorders, showcasing burgeoning therapeutic potential across multiple sectors.

Growth Drivers:

Expansion in the FGF market is driven by several factors including increased healthcare expenditure, technological advancements in biotechnology, and widening applications across therapeutic areas, indicating a robust trajectory for growth.

Challenges:

Despite the promising outlook, the market faces challenges such as regulatory hurdles, safety concerns regarding adverse effects, and limited commercialization infrastructure, which require strategic solutions and collaborative efforts from industry stakeholders.

Industry Trends:

Notable trends shaping the FGF market include the rise of personalized medicine in oncology, collaborative research initiatives among industry players, and the exploration of expanded therapeutic applications beyond traditional indications.

Opportunities:

Exploring novel therapeutic applications and expanding into emerging markets, particularly in the Asia Pacific region, present significant growth opportunities for players in the FGF market.

Regional Insights:

North America leads the market, followed by Europe and the Asia Pacific, with the Rest of the World showing potential for growth, driven by evolving healthcare infrastructure and increasing adoption of advanced medical technologies.

Key Players:

Major industry players such as Amgen, Pfizer, and Johnson & Johnson dominate the market landscape, leveraging continuous research and development efforts, strategic partnerships, and innovative product development to maintain their competitive edge.

Notable Developments:

Recent noteworthy developments in the FGF market include Amgen's RegenFibra(TM) for diabetic foot ulcers, Pfizer's RejuvaGlow(TM) dermal filler, and Johnson & Johnson's orthopaedic implants distribution agreement, reflecting ongoing innovation and investment in the sector.

Key Growth Determinants:

Expansion of FGF applications across various therapeutic areas, continuous technological advancements in biotechnology, and the increasing healthcare expenditure Globally are key determinants fueling market growth.

Major Growth Barriers:

Stringent regulatory requirements, safety concerns related to adverse effects, and limited commercialization infrastructure pose significant barriers to the growth of the FGF market, necessitating proactive measures and collaborative efforts to address these challenges.

Key Trends and Opportunities to Look at:

Key trends such as the personalized medicine boom in oncology, collaborative research initiatives, and the exploration of expanded therapeutic applications present exciting opportunities for industry players to capitalize on.

Regional Frontrunners:

North America leads the Global FGF market, benefitting from established regulatory frameworks and high healthcare expenditure, followed by Europe and the Asia Pacific, which hold immense promise due to factors such as government funding for innovation and a rapidly aging population.

Fairfield's Competitive Landscape Analysis:

The FGF market is fiercely competitive, with industry leaders such as Thermo Fisher Scientific, Merck KGaA (formerly Sigma-Aldrich), PeproTech, and others dominating the landscape. Key growth strategies include product development, strategic partnerships, and market expansion initiatives.

Leaders in Global Fibroblast Growth Factors Space:

Leading companies in the Global FGF market include Thermo Fisher Scientific, Merck KGaA (formerly Sigma-Aldrich), PeproTech, R&D Systems (a Bio-Techne brand), Abcam, Cell Signaling Technology, and Novus Biologicals, among others.

Global Fibroblast Growth Factors Market Segmentation:

By Product:

FGF1

FGF2

FGF3

FGF4

FGF7

FGF10

FGF11

FGF12

FGF13

FGF14

FGF15

FGF18

FGF19

FGF20

FGF23

By Application:

Oncology

Hematology

Wound Healing

Dermatology

Cardiovascular Disease & Diabetes

Cell Culture

By End User:

Pharmaceutical and Biotechnology Companies

Research Centers & Academic Institutes

Contract Manufacturing Organizations (CMO) and Contract Development and Manufacturing Organizations (CDMO)

By Region:

North America

Latin America

Europe

East Asia

South Asia

Oceania

Middle East and Africa

Table of Contents

1. Executive Summary

  • 1.1. Global Fibroblast Growth Factors Market Snapshot
  • 1.2. Future Projections
  • 1.3. Key Market Trends
  • 1.4. Regional Snapshot, by Value, 2023
  • 1.5. Analyst Recommendations

2. Market Overview

  • 2.1. Market Definitions and Segmentations
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Market Opportunities
  • 2.3. Value Chain Analysis
  • 2.4. Porter's Five Forces Analysis
  • 2.5. COVID-19 Impact Analysis
    • 2.5.1. Supply
    • 2.5.2. Demand
  • 2.6. Impact of Ukraine-Russia Conflict
  • 2.7. Economic Overview
    • 2.7.1. World Economic Projections
  • 2.8. PESTLE Analysis

3. Global Fibroblast Growth Factors Market Outlook, 2019 - 2031

  • 3.1. Global Fibroblast Growth Factors Market Outlook, by Product, Value (US$ Bn), 2019 - 2031
    • 3.1.1. Key Highlights
      • 3.1.1.1. FGF1
      • 3.1.1.2. FGF2
      • 3.1.1.3. FGF3
      • 3.1.1.4. FGF4
      • 3.1.1.5. FGF7
      • 3.1.1.6. FGF10
      • 3.1.1.7. FGF11
      • 3.1.1.8. FGF12
      • 3.1.1.9. FGF13
      • 3.1.1.10. FGF14
      • 3.1.1.11. FGF15
      • 3.1.1.12. FGF18
      • 3.1.1.13. FGF19
      • 3.1.1.14. FGF20
      • 3.1.1.15. FGF23
      • 3.1.1.16. Others
  • 3.2. Global Fibroblast Growth Factors Market Outlook, by Application, Value (US$ Bn), 2019 - 2031
    • 3.2.1. Key Highlights
      • 3.2.1.1. Oncology
      • 3.2.1.2. Hematology
      • 3.2.1.3. Wound Healing
      • 3.2.1.4. Dermatology
      • 3.2.1.5. Cardiovascular Disease & Diabetes
      • 3.2.1.6. Cell Culture
      • 3.2.1.7. Others
  • 3.3. Global Fibroblast Growth Factors Market Outlook, by End User, Value (US$ Bn), 2019 - 2031
    • 3.3.1. Key Highlights
      • 3.3.1.1. Pharmaceutical & Biotechnology Companies
      • 3.3.1.2. Research Centers & Academic Institutes
      • 3.3.1.3. CMOs & CDMOs
  • 3.4. Global Fibroblast Growth Factors Market Outlook, by Region, Value (US$ Bn), 2019 - 2031
    • 3.4.1. Key Highlights
      • 3.4.1.1. North America
      • 3.4.1.2. Europe
      • 3.4.1.3. Asia Pacific
      • 3.4.1.4. Latin America
      • 3.4.1.5. Middle East & Africa

4. North America Fibroblast Growth Factors Market Outlook, 2019 - 2031

  • 4.1. North America Fibroblast Growth Factors Market Outlook, by Product, Value (US$ Bn), 2019 - 2031
    • 4.1.1. Key Highlights
      • 4.1.1.1. FGF1
      • 4.1.1.2. FGF2
      • 4.1.1.3. FGF3
      • 4.1.1.4. FGF4
      • 4.1.1.5. FGF7
      • 4.1.1.6. FGF10
      • 4.1.1.7. FGF11
      • 4.1.1.8. FGF12
      • 4.1.1.9. FGF13
      • 4.1.1.10. FGF14
      • 4.1.1.11. FGF15
      • 4.1.1.12. FGF18
      • 4.1.1.13. FGF19
      • 4.1.1.14. FGF20
      • 4.1.1.15. FGF23
      • 4.1.1.16. Others
  • 4.2. North America Fibroblast Growth Factors Market Outlook, by Application, Value (US$ Bn), 2019 - 2031
    • 4.2.1. Key Highlights
      • 4.2.1.1. Oncology
      • 4.2.1.2. Hematology
      • 4.2.1.3. Wound Healing
      • 4.2.1.4. Dermatology
      • 4.2.1.5. Cardiovascular Disease & Diabetes
      • 4.2.1.6. Cell Culture
      • 4.2.1.7. Others
  • 4.3. North America Fibroblast Growth Factors Market Outlook, by End User, Value (US$ Bn), 2019 - 2031
    • 4.3.1. Key Highlights
      • 4.3.1.1. Pharmaceutical & Biotechnology Companies
      • 4.3.1.2. Research Centers & Academic Institutes
      • 4.3.1.3. CMOs & CDMOs
    • 4.3.2. BPS Analysis/Market Attractiveness Analysis
  • 4.4. North America Fibroblast Growth Factors Market Outlook, by Country, Value (US$ Bn), 2019 - 2031
    • 4.4.1. Key Highlights
      • 4.4.1.1. U.S. Fibroblast Growth Factors Market by Product, Value (US$ Bn), 2019 - 2031
      • 4.4.1.2. U.S. Fibroblast Growth Factors Market by Application, Value (US$ Bn), 2019 - 2031
      • 4.4.1.3. U.S. Fibroblast Growth Factors Market by End User, Value (US$ Bn), 2019 - 2031
      • 4.4.1.4. Canada Fibroblast Growth Factors Market by Product, Value (US$ Bn), 2019 - 2031
      • 4.4.1.5. Canada Fibroblast Growth Factors Market by Application, Value (US$ Bn), 2019 - 2031
      • 4.4.1.6. Canada Fibroblast Growth Factors Market by End User, Value (US$ Bn), 2019 - 2031
    • 4.4.2. BPS Analysis/Market Attractiveness Analysis

5. Europe Fibroblast Growth Factors Market Outlook, 2019 - 2031

  • 5.1. Europe Fibroblast Growth Factors Market Outlook, by Product, Value (US$ Bn), 2019 - 2031
    • 5.1.1. Key Highlights
      • 5.1.1.1. FGF1
      • 5.1.1.2. FGF2
      • 5.1.1.3. FGF3
      • 5.1.1.4. FGF4
      • 5.1.1.5. FGF7
      • 5.1.1.6. FGF10
      • 5.1.1.7. FGF11
      • 5.1.1.8. FGF12
      • 5.1.1.9. FGF13
      • 5.1.1.10. FGF14
      • 5.1.1.11. FGF15
      • 5.1.1.12. FGF18
      • 5.1.1.13. FGF19
      • 5.1.1.14. FGF20
      • 5.1.1.15. FGF23
      • 5.1.1.16. Others
  • 5.2. Europe Fibroblast Growth Factors Market Outlook, by Application, Value (US$ Bn), 2019 - 2031
    • 5.2.1. Key Highlights
      • 5.2.1.1. Oncology
      • 5.2.1.2. Hematology
      • 5.2.1.3. Wound Healing
      • 5.2.1.4. Dermatology
      • 5.2.1.5. Cardiovascular Disease & Diabetes
      • 5.2.1.6. Cell Culture
      • 5.2.1.7. Others
  • 5.3. Europe Fibroblast Growth Factors Market Outlook, by End User, Value (US$ Bn), 2019 - 2031
    • 5.3.1. Key Highlights
      • 5.3.1.1. Pharmaceutical & Biotechnology Companies
      • 5.3.1.2. Research Centers & Academic Institutes
      • 5.3.1.3. CMOs & CDMOs
    • 5.3.2. BPS Analysis/Market Attractiveness Analysis
  • 5.4. Europe Fibroblast Growth Factors Market Outlook, by Country, Value (US$ Bn), 2019 - 2031
    • 5.4.1. Key Highlights
      • 5.4.1.1. Germany Fibroblast Growth Factors Market by Product, Value (US$ Bn), 2019 - 2031
      • 5.4.1.2. Germany Fibroblast Growth Factors Market by Application, Value (US$ Bn), 2019 - 2031
      • 5.4.1.3. Germany Fibroblast Growth Factors Market by End User, Value (US$ Bn), 2019 - 2031
      • 5.4.1.4. U.K. Fibroblast Growth Factors Market by Product, Value (US$ Bn), 2019 - 2031
      • 5.4.1.5. U.K. Fibroblast Growth Factors Market by Application, Value (US$ Bn), 2019 - 2031
      • 5.4.1.6. U.K. Fibroblast Growth Factors Market by End User, Value (US$ Bn), 2019 - 2031
      • 5.4.1.7. France Fibroblast Growth Factors Market by Product, Value (US$ Bn), 2019 - 2031
      • 5.4.1.8. France Fibroblast Growth Factors Market by Application, Value (US$ Bn), 2019 - 2031
      • 5.4.1.9. France Fibroblast Growth Factors Market by End User, Value (US$ Bn), 2019 - 2031
      • 5.4.1.10. Italy Fibroblast Growth Factors Market by Product, Value (US$ Bn), 2019 - 2031
      • 5.4.1.11. Italy Fibroblast Growth Factors Market by Application, Value (US$ Bn), 2019 - 2031
      • 5.4.1.12. Italy Fibroblast Growth Factors Market by End User, Value (US$ Bn), 2019 - 2031
      • 5.4.1.13. Turkey Fibroblast Growth Factors Market by Product, Value (US$ Bn), 2019 - 2031
      • 5.4.1.14. Turkey Fibroblast Growth Factors Market by Application, Value (US$ Bn), 2019 - 2031
      • 5.4.1.15. Turkey Fibroblast Growth Factors Market by End User, Value (US$ Bn), 2019 - 2031
      • 5.4.1.16. Russia Fibroblast Growth Factors Market by Product, Value (US$ Bn), 2019 - 2031
      • 5.4.1.17. Russia Fibroblast Growth Factors Market by Application, Value (US$ Bn), 2019 - 2031
      • 5.4.1.18. Russia Fibroblast Growth Factors Market by End User, Value (US$ Bn), 2019 - 2031
      • 5.4.1.19. Rest of Europe Fibroblast Growth Factors Market by Product, Value (US$ Bn), 2019 - 2031
      • 5.4.1.20. Rest of Europe Fibroblast Growth Factors Market by Application, Value (US$ Bn), 2019 - 2031
      • 5.4.1.21. Rest of Europe Fibroblast Growth Factors Market by End User, Value (US$ Bn), 2019 - 2031
    • 5.4.2. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Fibroblast Growth Factors Market Outlook, 2019 - 2031

  • 6.1. Asia Pacific Fibroblast Growth Factors Market Outlook, by Product, Value (US$ Bn), 2019 - 2031
    • 6.1.1. Key Highlights
      • 6.1.1.1. FGF1
      • 6.1.1.2. FGF2
      • 6.1.1.3. FGF3
      • 6.1.1.4. FGF4
      • 6.1.1.5. FGF7
      • 6.1.1.6. FGF10
      • 6.1.1.7. FGF11
      • 6.1.1.8. FGF12
      • 6.1.1.9. FGF13
      • 6.1.1.10. FGF14
      • 6.1.1.11. FGF15
      • 6.1.1.12. FGF18
      • 6.1.1.13. FGF19
      • 6.1.1.14. FGF20
      • 6.1.1.15. FGF23
      • 6.1.1.16. Others
  • 6.2. Asia Pacific Fibroblast Growth Factors Market Outlook, by Application, Value (US$ Bn), 2019 - 2031
    • 6.2.1. Key Highlights
      • 6.2.1.1. Oncology
      • 6.2.1.2. Hematology
      • 6.2.1.3. Wound Healing
      • 6.2.1.4. Dermatology
      • 6.2.1.5. Cardiovascular Disease & Diabetes
      • 6.2.1.6. Cell Culture
      • 6.2.1.7. Others
  • 6.3. Asia Pacific Fibroblast Growth Factors Market Outlook, by End User, Value (US$ Bn), 2019 - 2031
    • 6.3.1. Key Highlights
      • 6.3.1.1. Pharmaceutical & Biotechnology Companies
      • 6.3.1.2. Research Centers & Academic Institutes
      • 6.3.1.3. CMOs & CDMOs
    • 6.3.2. BPS Analysis/Market Attractiveness Analysis
  • 6.4. Asia Pacific Fibroblast Growth Factors Market Outlook, by Country, Value (US$ Bn), 2019 - 2031
    • 6.4.1. Key Highlights
      • 6.4.1.1. China Fibroblast Growth Factors Market by Product, Value (US$ Bn), 2019 - 2031
      • 6.4.1.2. China Fibroblast Growth Factors Market by Application, Value (US$ Bn), 2019 - 2031
      • 6.4.1.3. China Fibroblast Growth Factors Market by End User, Value (US$ Bn), 2019 - 2031
      • 6.4.1.4. Japan Fibroblast Growth Factors Market by Product, Value (US$ Bn), 2019 - 2031
      • 6.4.1.5. Japan Fibroblast Growth Factors Market by Application, Value (US$ Bn), 2019 - 2031
      • 6.4.1.6. Japan Fibroblast Growth Factors Market by End User, Value (US$ Bn), 2019 - 2031
      • 6.4.1.7. South Korea Fibroblast Growth Factors Market by Product, Value (US$ Bn), 2019 - 2031
      • 6.4.1.8. South Korea Fibroblast Growth Factors Market by Application, Value (US$ Bn), 2019 - 2031
      • 6.4.1.9. South Korea Fibroblast Growth Factors Market by End User, Value (US$ Bn), 2019 - 2031
      • 6.4.1.10. India Fibroblast Growth Factors Market by Product, Value (US$ Bn), 2019 - 2031
      • 6.4.1.11. India Fibroblast Growth Factors Market by Application, Value (US$ Bn), 2019 - 2031
      • 6.4.1.12. India Fibroblast Growth Factors Market by End User, Value (US$ Bn), 2019 - 2031
      • 6.4.1.13. Southeast Asia Fibroblast Growth Factors Market by Product, Value (US$ Bn), 2019 - 2031
      • 6.4.1.14. Southeast Asia Fibroblast Growth Factors Market by Application, Value (US$ Bn), 2019 - 2031
      • 6.4.1.15. Southeast Asia Fibroblast Growth Factors Market by End User, Value (US$ Bn), 2019 - 2031
      • 6.4.1.16. Rest of Asia Pacific Fibroblast Growth Factors Market by Product, Value (US$ Bn), 2019 - 2031
      • 6.4.1.17. Rest of Asia Pacific Fibroblast Growth Factors Market by Application, Value (US$ Bn), 2019 - 2031
      • 6.4.1.18. Rest of Asia Pacific Fibroblast Growth Factors Market by End User, Value (US$ Bn), 2019 - 2031
    • 6.4.2. BPS Analysis/Market Attractiveness Analysis

7. Latin America Fibroblast Growth Factors Market Outlook, 2019 - 2031

  • 7.1. Latin America Fibroblast Growth Factors Market Outlook, by Product, Value (US$ Bn), 2019 - 2031
    • 7.1.1. Key Highlights
      • 7.1.1.1. FGF1
      • 7.1.1.2. FGF2
      • 7.1.1.3. FGF3
      • 7.1.1.4. FGF4
      • 7.1.1.5. FGF7
      • 7.1.1.6. FGF10
      • 7.1.1.7. FGF11
      • 7.1.1.8. FGF12
      • 7.1.1.9. FGF13
      • 7.1.1.10. FGF14
      • 7.1.1.11. FGF15
      • 7.1.1.12. FGF18
      • 7.1.1.13. FGF19
      • 7.1.1.14. FGF20
      • 7.1.1.15. FGF23
      • 7.1.1.16. Others
  • 7.2. Latin America Fibroblast Growth Factors Market Outlook, by Application, Value (US$ Bn), 2019 - 2031
    • 7.2.1. Key Highlights
      • 7.2.1.1. Oncology
      • 7.2.1.2. Hematology
      • 7.2.1.3. Wound Healing
      • 7.2.1.4. Dermatology
      • 7.2.1.5. Cardiovascular Disease & Diabetes
      • 7.2.1.6. Cell Culture
      • 7.2.1.7. Others
  • 7.3. Latin America Fibroblast Growth Factors Market Outlook, by End User, Value (US$ Bn), 2019 - 2031
    • 7.3.1. Key Highlights
      • 7.3.1.1. Pharmaceutical & Biotechnology Companies
      • 7.3.1.2. Research Centers & Academic Institutes
      • 7.3.1.3. CMOs & CDMOs
    • 7.3.2. BPS Analysis/Market Attractiveness Analysis
  • 7.4. Latin America Fibroblast Growth Factors Market Outlook, by Country, Value (US$ Bn), 2019 - 2031
    • 7.4.1. Key Highlights
      • 7.4.1.1. Brazil Fibroblast Growth Factors Market by Product, Value (US$ Bn), 2019 - 2031
      • 7.4.1.2. Brazil Fibroblast Growth Factors Market by Application, Value (US$ Bn), 2019 - 2031
      • 7.4.1.3. Brazil Fibroblast Growth Factors Market by End User, Value (US$ Bn), 2019 - 2031
      • 7.4.1.4. Mexico Fibroblast Growth Factors Market by Product, Value (US$ Bn), 2019 - 2031
      • 7.4.1.5. Mexico Fibroblast Growth Factors Market by Application, Value (US$ Bn), 2019 - 2031
      • 7.4.1.6. Mexico Fibroblast Growth Factors Market by End User, Value (US$ Bn), 2019 - 2031
      • 7.4.1.7. Argentina Fibroblast Growth Factors Market by Product, Value (US$ Bn), 2019 - 2031
      • 7.4.1.8. Argentina Fibroblast Growth Factors Market by Application, Value (US$ Bn), 2019 - 2031
      • 7.4.1.9. Argentina Fibroblast Growth Factors Market by End User, Value (US$ Bn), 2019 - 2031
      • 7.4.1.10. Rest of Latin America Fibroblast Growth Factors Market by Product, Value (US$ Bn), 2019 - 2031
      • 7.4.1.11. Rest of Latin America Fibroblast Growth Factors Market by Application, Value (US$ Bn), 2019 - 2031
      • 7.4.1.12. Rest of Latin America Fibroblast Growth Factors Market by End User, Value (US$ Bn), 2019 - 2031
    • 7.4.2. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Fibroblast Growth Factors Market Outlook, 2019 - 2031

  • 8.1. Middle East & Africa Fibroblast Growth Factors Market Outlook, by Product, Value (US$ Bn), 2019 - 2031
    • 8.1.1. Key Highlights
      • 8.1.1.1. FGF1
      • 8.1.1.2. FGF2
      • 8.1.1.3. FGF3
      • 8.1.1.4. FGF4
      • 8.1.1.5. FGF7
      • 8.1.1.6. FGF10
      • 8.1.1.7. FGF11
      • 8.1.1.8. FGF12
      • 8.1.1.9. FGF13
      • 8.1.1.10. FGF14
      • 8.1.1.11. FGF15
      • 8.1.1.12. FGF18
      • 8.1.1.13. FGF19
      • 8.1.1.14. FGF20
      • 8.1.1.15. FGF23
      • 8.1.1.16. Others
  • 8.2. Middle East & Africa Fibroblast Growth Factors Market Outlook, by Application, Value (US$ Bn), 2019 - 2031
    • 8.2.1. Key Highlights
      • 8.2.1.1. Oncology
      • 8.2.1.2. Hematology
      • 8.2.1.3. Wound Healing
      • 8.2.1.4. Dermatology
      • 8.2.1.5. Cardiovascular Disease & Diabetes
      • 8.2.1.6. Cell Culture
      • 8.2.1.7. Others
  • 8.3. Middle East & Africa Fibroblast Growth Factors Market Outlook, by End User, Value (US$ Bn), 2019 - 2031
    • 8.3.1. Key Highlights
      • 8.3.1.1. Pharmaceutical & Biotechnology Companies
      • 8.3.1.2. Research Centers & Academic Institutes
      • 8.3.1.3. CMOs & CDMOs
    • 8.3.2. BPS Analysis/Market Attractiveness Analysis
  • 8.4. Middle East & Africa Fibroblast Growth Factors Market Outlook, by Country, Value (US$ Bn), 2019 - 2031
    • 8.4.1. Key Highlights
      • 8.4.1.1. GCC Fibroblast Growth Factors Market by Product, Value (US$ Bn), 2019 - 2031
      • 8.4.1.2. GCC Fibroblast Growth Factors Market by Application, Value (US$ Bn), 2019 - 2031
      • 8.4.1.3. GCC Fibroblast Growth Factors Market by End User, Value (US$ Bn), 2019 - 2031
      • 8.4.1.4. South Africa Fibroblast Growth Factors Market by Product, Value (US$ Bn), 2019 - 2031
      • 8.4.1.5. South Africa Fibroblast Growth Factors Market by Application, Value (US$ Bn), 2019 - 2031
      • 8.4.1.6. South Africa Fibroblast Growth Factors Market by End User, Value (US$ Bn), 2019 - 2031
      • 8.4.1.7. Egypt Fibroblast Growth Factors Market by Product, Value (US$ Bn), 2019 - 2031
      • 8.4.1.8. Egypt Fibroblast Growth Factors Market by Application, Value (US$ Bn), 2019 - 2031
      • 8.4.1.9. Egypt Fibroblast Growth Factors Market by End User, Value (US$ Bn), 2019 - 2031
      • 8.4.1.10. Nigeria Fibroblast Growth Factors Market by Product, Value (US$ Bn), 2019 - 2031
      • 8.4.1.11. Nigeria Fibroblast Growth Factors Market by Application, Value (US$ Bn), 2019 - 2031
      • 8.4.1.12. Nigeria Fibroblast Growth Factors Market by End User, Value (US$ Bn), 2019 - 2031
      • 8.4.1.13. Rest of Middle East & Africa Fibroblast Growth Factors Market by Product, Value (US$ Bn), 2019 - 2031
      • 8.4.1.14. Rest of Middle East & Africa Fibroblast Growth Factors Market by Application, Value (US$ Bn), 2019 - 2031
      • 8.4.1.15. Rest of Middle East & Africa Fibroblast Growth Factors Market by End User, Value (US$ Bn), 2019 - 2031
    • 8.4.2. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

  • 9.1. By End User vs by Application Heatmap
  • 9.2. Company Market Share Analysis, 2023
  • 9.3. Competitive Dashboard
  • 9.4. Company Profiles
    • 9.4.1. Thermo Fisher Scientific
      • 9.4.1.1. Company Overview
      • 9.4.1.2. Product Portfolio
      • 9.4.1.3. Financial Overview
      • 9.4.1.4. Business Strategies and Development
    • 9.4.2. Sigma-Aldrich (now part of Merck KGaA)
      • 9.4.2.1. Company Overview
      • 9.4.2.2. Product Portfolio
      • 9.4.2.3. Financial Overview
      • 9.4.2.4. Business Strategies and Development
    • 9.4.3. PeproTech
      • 9.4.3.1. Company Overview
      • 9.4.3.2. Product Portfolio
      • 9.4.3.3. Financial Overview
      • 9.4.3.4. Business Strategies and Development
    • 9.4.4. R&D Systems (a Bio-Techne brand)
      • 9.4.4.1. Company Overview
      • 9.4.4.2. Product Portfolio
      • 9.4.4.3. Financial Overview
      • 9.4.4.4. Business Strategies and Development
    • 9.4.5. Abcam
      • 9.4.5.1. Company Overview
      • 9.4.5.2. Product Portfolio
      • 9.4.5.3. Financial Overview
      • 9.4.5.4. Business Strategies and Development
    • 9.4.6. Cell Signaling Technology
      • 9.4.6.1. Company Overview
      • 9.4.6.2. Product Portfolio
      • 9.4.6.3. Financial Overview
      • 9.4.6.4. Business Strategies and Development
    • 9.4.7. Novus Biologicals
      • 9.4.7.1. Company Overview
      • 9.4.7.2. Product Portfolio
      • 9.4.7.3. Financial Overview
      • 9.4.7.4. Business Strategies and Development

10. Appendix

  • 10.1. Research Methodology
  • 10.2. Report Assumptions
  • 10.3. Acronyms and Abbreviations
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제